Inhibition of virus entry: An antiviral mechanism of emerging prominence

Current Opinion in Investigational Drugs

Volumn 7, Issue 2, 2006, Pages 106-108

  Koszalka, George W ^a   Meanwell, Nicholas A ^b  

^a Trimeris Inc   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 070; AMD 3451; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BMS 433771; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DENDRIMER; ENFUVIRTIDE; MARAVIROC; PRO 140; PRO 2000; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC;

CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFLUENZA; LIFE CYCLE; NONHUMAN; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ADSORPTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; CELL ADHESION; DRUG DESIGN; HIV; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MEMBRANE FUSION; PEPTIDE FRAGMENTS; PIPERAZINES; RECEPTORS, CCR5;

EID: 32544438438     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Smith AE, Helenius A: How viruses enter animal cells. Science (2004) 304(5668):237-242.
2. Mammen N, Choi S-K, Whitesides GM: Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed (1998) 37(20):2754-2794.
3. Wang H-GH, Williams RE, Lin P-F: A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Curr Pharm Des (2004) 10(15):1785-1793.
4. Bursavich MG, Rich DH: Designing non-peptide peptidomimetics in the 21st century: Inhibitors targeting conformational ensembles. J Med Chem (2002) 45(3):541-558.
5. Bristol-Myers Squibb Co: Bristol-Myers Squibb presents data providing proof-of-concept for novel experimental oral attachment inhibitor, a potential new class of antiretroviral therapy. Press Release (2004): February 11.
6. Norris D, Morales J, Gathe J, Godofsky E, Garcia F, Hardwicke R, Jackson J, Lewis S, Paradiso L: TNX-355 in combination with optimized background regimen (OBR) exhibits greater antiviral activity than OBR alone in HIV-treatment experienced patients. ICAAC (2005) 45:Abs LB2-26.
7. Greenberg M, Cammack N, Salgo M, Smiley L: HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol (2004) 14(5):321-337.
8. Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu K-L, Ouellet C, Dextraze P et al: Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol (1997) 71(5):4062-4070.
9. Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem (2001) 70:777-810.
10. Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, Hou XS, Schleif WA, Miller MD, Geleziunas R, Pessi A: Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci USA (2005) 102(36):12903-12908.
11. Ernst JT, Kutzki O, Debnath AK, Jiang S, Lu H, Hamilton AD: Design of a protein surface antagonist based on α-helix mimicry: Inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed (2002) 41(2):278-281.
12. Cianci C, Langley DR, Dischino DD, Sun Y, Yu K-L, Stanley A, Roach J, Li Z, Dalterio R, Colonno R, Meanwell NA, Krystal M: Targeting a binding pocket within the trimer-of-hairpins: Small molecule inhibition of viral fusion. Proc Natl Acad Sci USA (2004) 101(42): 15046-15051.